Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern.

Publication date: Jun 28, 2023

Sequential infections with SARS-CoV-2 variants such as Alpha, Delta, Omicron and its sublineages may cause high morbidity, so it is necessary to develop vaccines that can protect against both wild-type (WT) virus and its variants. Mutations in SARS-CoV-2’s spike protein can easily alter viral transmission and vaccination effectiveness. In this study, we designed full-length spike mRNAs for WT, Alpha, Delta, and BA. 5 variants and integrated each into monovalent or bivalent mRNA-lipid nanoparticle vaccines. A pseudovirus neutralization assay was conducted on immunized mouse sera in order to examine the neutralizing potential of each vaccine. Monovalent mRNA vaccines were only effective against the same type of virus. Interestingly, monovalent BA. 5 vaccination could neutralize BF. 7 and BQ. 1.1. Moreover, WT, Alpha, Delta, BA. 5, and BF. 7 pseudoviruses were broadly neutralized by bivalent mRNA vaccinations, such as BA. 5 + WT, BA. 5 + Alpha, and BA. 5 + Delta. In particular, BA. 5 + WT exhibited high neutralization against most variants of concern (VOCs) in a pseudovirus neutralization assay. Our results show that combining two mRNA sequences may be an effective way to develop a broadly protective SARS-CoV-2 vaccine against a wide range of variant types. Importantly, we provide the optimal combination regimen and propose a strategy that may prove useful in combating future VOCs.

Open Access PDF

Concepts Keywords
Biomed Bivalent mRNA vaccines
Future SARS-CoV-2
Morbidity Vaccine efficacy


Type Source Name
disease VO vaccine effectiveness
disease MESH infections
disease MESH morbidity
disease VO vaccination
disease VO effectiveness
disease IDO assay
disease VO immunized
disease VO vaccine
disease VO effective
pathway REACTOME Reproduction
disease VO vaccine efficacy
disease MESH COVID 19 pandemic
drug DRUGBANK Spinosad
disease IDO infection
disease VO vaccinated
disease VO USA
disease VO Glycoprotein
disease IDO host
drug DRUGBANK Coenzyme M
disease VO titer
disease VO antibody titer
disease IDO production
disease IDO facility
drug DRUGBANK Troleandomycin
disease IDO site
drug DRUGBANK Ethanol
drug DRUGBANK Microcrystalline cellulose
drug DRUGBANK Cholesterol
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Sodium acetate
disease VO Canada
drug DRUGBANK Tretamine
drug DRUGBANK Copper
drug DRUGBANK Activated charcoal
drug DRUGBANK Nitrogen
disease VO efficiency
disease VO immunization
disease VO injection
drug DRUGBANK Human Serum Albumin
disease IDO blood
disease VO Viruses
disease VO device
drug DRUGBANK Albendazole
drug DRUGBANK Trestolone
disease MESH dissociation
disease IDO cell
drug DRUGBANK Esomeprazole
disease IDO process
disease VO dose
disease VO time
disease VO ineffective
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Angiotensin II
drug DRUGBANK Proline
disease VO protocol
disease VO URE
disease VO unvaccinated
drug DRUGBANK Iron
disease VO efficient
disease VO Severe acute respiratory syndrome coronavirus 2
disease IDO intervention
disease VO CoronaVac
disease VO Ad26.COV2.S
drug DRUGBANK Gold
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Guanosine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *